Skip to Main Content

REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects (REPRISE IV)

Conditions

Diseases of the Cardiovascular System

Phase Pilot

What is the purpose of this trial?

Brief Summary:

REPRISE IV: REpositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of LOTUS Edge Valve System in IntermediatE Surgical Risk Subjects

  • Trial with
    Boston Scientific Corporation
  • Start Date
    11/11/2019
  • End Date
    01/29/2021
Trial Image

For more information about this study, contact:

Linda Levesque

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    11/13/2019
  • Study HIC
    #2000025973